Armed With Two Patents,
Psycheceutical Plans To Transform
Psychedelic Drug Delivery
PRESS ROOM
PSYCHECEUTICAL IN THE NEWS
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption
Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents
Psycheceutical Welcomes Translational Research Expert Zachary Clayton To Its Advisory Board
PODCASTS
PRESS RELEASES
Psycheceutical Completes Acquisition by Blue Water Ventures International
Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
Read More Psycheceutical Grows Scientific Advisory Board With Addition of Translational Research Expert, Zachary Clayton, PhD
Psycheceutical, Inc., today announced the addition of Zachary Clayton, PhD, to its scientific advisory board.
Read More Psycheceutical, Inc. Expands Executive Team With Announcement of New Advisory Board Appointments
Psycheceutical, Inc., today announced the growth of its esteemed board with two new appointments, Dr. Ronald Aung-Din and Dr. John Kutzko.
Read More Psycheceutical, Inc. Announces New Patents That Enable Psychedelic Compounds to Be Administered as Pharmaceutical Medicines
Psycheceutical, Inc., today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds.
Read More